Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Insider Robert Berman Sells 125,000 Shares

researchsnappy by researchsnappy
January 8, 2020
in Healthcare Research
0
Eric Aguiar Sells 3,537 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Biohaven Pharmaceutical logoBiohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 125,000 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $53.22, for a total value of $6,652,500.00. Following the completion of the transaction, the insider now directly owns 125,341 shares in the company, valued at approximately $6,670,648.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Biohaven Pharmaceutical stock traded up $2.18 during midday trading on Tuesday, reaching $55.92. The stock had a trading volume of 645,368 shares, compared to its average volume of 667,844. The company has a fifty day moving average of $54.42 and a 200 day moving average of $46.07. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -9.09 and a beta of 0.43. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $34.06 and a 52-week high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.47). On average, equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -7.61 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of BHVN. Nuveen Asset Management LLC acquired a new stake in Biohaven Pharmaceutical in the 2nd quarter worth approximately $38,799,000. Eventide Asset Management LLC lifted its holdings in shares of Biohaven Pharmaceutical by 98.5% during the third quarter. Eventide Asset Management LLC now owns 1,634,000 shares of the company’s stock worth $68,170,000 after buying an additional 811,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Biohaven Pharmaceutical by 28.8% during the third quarter. State Street Corp now owns 2,044,943 shares of the company’s stock worth $85,315,000 after buying an additional 456,986 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Biohaven Pharmaceutical by 236.8% during the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock worth $23,892,000 after buying an additional 383,594 shares during the last quarter. Finally, Brown Advisory Inc. lifted its holdings in shares of Biohaven Pharmaceutical by 60.7% during the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock worth $44,144,000 after buying an additional 380,764 shares during the last quarter. Hedge funds and other institutional investors own 92.83% of the company’s stock.

Several research firms have weighed in on BHVN. Piper Jaffray Companies reissued a “buy” rating and issued a $100.00 target price on shares of Biohaven Pharmaceutical in a research note on Monday, December 23rd. William Blair reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, December 10th. Wedbush began coverage on Biohaven Pharmaceutical in a research note on Thursday, December 12th. They issued an “outperform” rating and a $75.00 target price on the stock. Leerink Swann increased their target price on Biohaven Pharmaceutical from $62.00 to $64.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. Finally, Cantor Fitzgerald raised their price target on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, October 28th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $71.42.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: How accurate is the Rule of 72?

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Growth Differentiation Factor 15 as a Useful Biomarker of Heart Failure in Young Patients with Unrepaired Congenital Heart Disease of Left to Right Shunt

Next Post

Hedge Fund Consensus Stocks vs. Roku, Inc. (ROKU) In 2019

Next Post
Hedge Fund Consensus Stocks vs. Roku, Inc. (ROKU) In 2019

Hedge Fund Consensus Stocks vs. Roku, Inc. (ROKU) In 2019

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com